Drug Profile
PW 2101
Latest Information Update: 04 Jul 2005
Price :
$50
*
At a glance
- Originator Penwest Pharmaceuticals
- Class Antihypertensives
- Mechanism of Action Beta-adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 04 Jul 2005 Discontinued - Preregistration for Hypertension in USA (PO)
- 04 Jul 2005 Penwest has received a non-approvable letter from the US FDA for PW 2101 in hypertension
- 27 Apr 2005 PW 2101 has been licensed to Prism Pharmaceuticals in the US and Canada